BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06592768 (briquilimab in Allergic Asthma): BVCT ex-ante prediction vs. reported outcome

On 26 Apr 2025, BioinvestGPT's BVCT predicted technical partial failure and commercial failure for this trial. The 2 Dec 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically maybe significant yet commercially insufficient.

Clinical Trial

NCTID
NCT06592768
Acronym
ETESIAN
Drug Name
briquilimab
Drug MoA
aglycosylated anti-cKIT inhibitor
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Respiratory Tract Diseases
Indication
Allergic Asthma
Human Patients
17
Sponsor
Jasper Therapeutics
Phase
Phase 1

Prediction of , index 1995

Prospective Prediction
Prediction Index
1995
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit allergy-induced LAR/EAR non-superior to SoC)
Technical Prediction
partial FAILURE (statistically maybe significant yet very weak clinical benefit in allergy-induced LAR/EAR compared with placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
220 days in advance
Readout Data Interpretation
briquilimab showed positive preliminary data (single 180mg SC briquilimab gave reductions in sputum eosinophils at 6 and 12 weeks plus FEV1 improvement; well tolerated), yet not sufficient for advancing any future clinical studies
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically maybe significant yet commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
Phase
Phase 1
Status
Terminated
Enrollment
17
Lead sponsor
Jasper Therapeutics, Inc.
Conditions
Allergic Asthma
Interventions
DRUG: Briquilimab; OTHER: Placebo Comparator
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2024-11-26
Primary completion
2025-08-11
Completion
2025-08-11
Primary outcomes
  • To evaluate the safety and tolerability of briquilimab in mild-to-moderate asthmatic participants (From signing the informed consent form (ICF) through end of trial (EOT) visit (up to 4.5 months))
  • To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LAR (3-7 hours after allergen challenge between Briquilimab and Placebo at week 6)
  • To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LAR (3-7 hours after allergen challenge between Briquilimab and Placebo at week 6)

NCT06592768 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials